key: cord-0707022-mgx3p0jt authors: Peters, Thomas G.; Bragg‐Gresham, Jennifer L.; Klopstock, Annie C.; Roberts, John P.; Chertow, Glenn; McCormick, Frank; Held, Philip J. title: Estimated impact of novel coronavirus‐19 and transplant center inactivity on end‐stage renal disease‐related patient mortality in the United States date: 2021-05-31 journal: Clin Transplant DOI: 10.1111/ctr.14292 sha: 5e4e3c208fe50dffb13cd06a4fa8f8c5b2c03ed6 doc_id: 707022 cord_uid: mgx3p0jt To predict whether the COVID‐19 pandemic and transplant center responses could have resulted in preventable deaths, we analyzed registry information of the US end‐stage renal disease (ESRD) patient population awaiting kidney transplantation. Data were from the Organ Procurement and Transplantation Network (OPTN), the US Centers for Disease Control and Prevention, and the United States Renal Data System. Based on 2019 OPTN reports, annualized reduction in kidney transplantation of 25%–100% could result in excess deaths of wait‐listed (deceased donor) transplant candidates from 84 to 337 and living donor candidate excess deaths from 35 to 141 (total 119–478 potentially preventable deaths of transplant candidates). Changes in transplant activity due to COVID‐19 varied with some centers shutting down while others simply heeded known or suspected pandemic risks. Understanding potential excess mortality for ESRD transplant candidates when circumstances compel curtailment of transplant activity may inform policy and procedural aspects of organ transplant systems allowing ways to best inform patients and families as to potential risks in shuttering organ transplant activity. Considering that more than 700 000 Americans have ESRD with 100 000 awaiting a kidney transplant, our highest annual estimate of 478 excess total deaths from postponing kidney transplantation seems modest. There was no extramural support for this research. Each author contributed time and effort voluntarily. Except for the authors, no person or institution had a role in defining the content of the manuscript. To predict whether the COVID-19 pandemic and transplant center responses could have resulted in preventable deaths, we analyzed registry information of the US end-stage renal disease (ESRD) patient population awaiting kidney transplantation. Data were from the Organ Procurement and Transplantation Network (OPTN), the System. Based on 2019 OPTN reports, annualized reduction in kidney transplantation of 25%-100% could result in excess deaths of wait-listed (deceased donor) transplant candidates from 84 to 337 and living donor candidate excess deaths from 35 to 141 (total 119-478 potentially preventable deaths of transplant candidates). Changes in transplant activity due to COVID-19 varied with some centers shutting down while others simply heeded known or suspected pandemic risks. Understanding potential excess mortality for ESRD transplant candidates when circumstances compel curtailment of transplant activity may inform policy and procedural aspects of organ transplant systems allowing ways to best inform patients and families as to potential risks in shuttering organ transplant activity. Considering that more than 700 000 Americans have ESRD with 100 000 awaiting a kidney transplant, our highest annual estimate of 478 excess total deaths from postponing kidney transplantation seems modest. COVID-19, excess mortality, kidney transplant candidates, transplant program activity who might be expected to die due to delay in receipt of a living or deceased donor kidney. 8 Estimates of US deaths due to delays and cancelations of kidney transplantation may not only shed light on lost opportunities to save lives, but also point to revisions of policies and planning which could address future interruptions in the practice of organ transplantation. Especially with ESRD transplant candidates, the ubiquitous asset of US dialysis may compel an unsubstantiated assessment that kidney transplantation can wait because no patient will suffer or die while waiting longer for a kidney. Other factors such as reduced social interactions, organ donation, and recovery imperatives, as well as the already-stated program cancelations may support such a temporizing approach. While ESRD professionals understand the mortality risks associated with ongoing dialysis, there is little to enlighten patients, caregivers, or families about additive risks if kidney transplantation were partially or completely curtailed for some period of time. This study seeks to predict the possible loss of US lives due to the delay and cancelation of kidney transplantation. The analyses are based on past measures of known mortality risks among different categories of patients receiving maintenance dialysis, those who are wait-listed for a deceased donor kidney, those scheduling a living donor transplant, and kidney recipients already transplanted. We sought to estimate the number of excess deaths related to various levels of interruptions to kidney transplant care in circumstances such as the COVID-19 pandemic. Calculations considered that a patient who is on the deceased donor waitlist and is subsequently transplanted exchanges one risk (dialysis mortality) for another typically lower risk (transplant mortality). The higher mortality estimates are based on the delta (Δ) loss rate where the former is the mortality for wait-listed dialysis patients and the latter is the loss rate experienced if patients had been transplanted. The Δ mortality rate is based on the reported values of mortality risk for wait-listed patients in 2016 (5.3%/year), compared with the lower transplant mortality risk for a patient with a successfully functioning transplant (3.26%/year). 12 Therefore, the difference (5.30% − 3.26% = 2.04%) in mortality was rounded to 2 percentage points. Stated otherwise, the lower risk of dying with a kidney transplant was subtracted from the higher risk of dying while on dialysis but wait-listed for a kidney, the difference being excess mortality. For completeness and comparison, mortality rates for the general population and Medicare beneficiaries over age 65 years were noted. Counts of excess mortality were estimated for a range of possible reductions in transplant services (25%-100%). The authors of this manuscript have no conflicts of interest to disclose. Research idea and study design: TGP, JLB-G The data that support the findings of this study are available at: Early impact of COVID-19 on transplant center practices and policies in the United States Factors associated with surgical mortality and complications among patients with and without coronavirus disease 2019 (COVID-19) in Italy Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States COVID-19: A global transplant perspective on successfully navigating a pandemic Mitigating the risks of surgery during the COVID-19 pandemic Utilization of deceased donors during a pandemic: an argument against using SARS-CoV-2-positive donors False negative teats for SARS-CoV-2 infection-challenges and implications Early impact of COVID 19 on solid organ transplantation in the United States OPTN 2019 annual data report Centers for Disease Control and Prevention: National Center for Health Statistics. FastStats, life stages and populations, deaths US renal data system chapter 3: morbidity and mortality in patients with CKD USRDS Annual Data Report: Epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Personal communication: COVID assessment. National Kidney Registry Now is the time for the organ procurement and transplantation network to change regulatory policy to effectively increase transplantation in the United States: Carpe Diem The OPTN deceased donor potential study: implications for policy and practice Factors affecting the waiting time of cadaveric kidney transplant candidates in the United States COVID-19 in kidney transplantation: Epidemiology, management considerations, and the impact on kidney transplant practice Systemic review: Kidney transplantation compared with dialysis in clinically relevant outcomes Outcomes of renal transplant recipients with SARS-CoV-2 infection in the eye of the storm: a comparative study with waitlisted patients HHS reports progress on President Trump's Advancing American Kidney Health Initiative How to cite this article: Peters TG Estimated impact of novel coronavirus-19 and transplant center inactivity on end-stage renal disease-related patient mortality in the United States